



Organized by

**The Egyptian Society of
Hepatology, Gastroenterology
& Infectious Diseases in Alexandria**



**LUXOR
2017**

FIRST MEDITERRANEAN Forum of Hepatitis and GERD

STEIGENBERGER HOTEL, LUXOR - MARCH 8-11, 2017



Mediterranean forum of Hepatitis and GERD is a unique update meeting for two topics only allowing experts to present cutting edge knowledge about both topics.

On behalf of ESHGID we invite all experts and interested doctors to participate in the First Mediterranean Forum of Hepatitis and GERD that will be held in Luxor, March 8-11, 2017, to discuss Hepatitis and GERD updates.

Sessions will be specialized and very updated discussing the most important topics in hepatitis and gastro esophageal reflux disease.

All participants are encouraged to interact with expertise. Also young doctors and investigators are welcomed to participate and present short update lectures in each session provided that they will send suggestions very soon. We specified special session for poster presentations that will be discussed and guided by eminent experts.



BOARD OF ESHGID

President

Prof. Hilmy Abaza

Treasurer

Prof. Siham Abdel-Reheim

Members

Prof. Abdel-Fattah Hano

Prof. Ahmed Shawki

Prof. Ahmed Zaid

Prof. Alaa Abdo

Prof. Amany El-Yamani

Prof. Doaa El-Wazzan

Secretary General

Prof. Yousry Taher

Vice President

Prof. Mostafa EL-Hennawy

Prof. Farouk Mekki

Prof. Fatahllah Sedki

Prof. Hassan El-Bahrawy

Prof. Mohamed Kassem

Prof. Nahed Baddor

LUXOR 2017



TOPICS OF 1ST DAY

HEPATITIS UPDATES

SESSION 1

- Early vs late treatment for HCV.
- Screening for HCV among Egyptian population.
- Relapse after DAAs treatment highlights of management and problems.
- Pitfalls in management of HCV.

SESSION 2

- Treatment of advanced HCV still a difficult problem what can we do.
- Available & new drugs what about the future of relapses & mutations.
- Facts and fakes about HCV cure.
- DAAs and HCC facts and fakes.

SESSION 3

- Persistent of HCV RNA after SVR after DAAs treatment.
- HBV new in the near future?
- Nucleotides (tides) are still drugs of choice for HBV treatment.
- Point of no return in chronic HCV liver disease clinical and Histopathologic point of views.

SESSION 4

- Autoimmune hepatitis /Autoimmune cholangitis.
- Primary biliary cholangitis diagnosis and update management.
- Sclerosing cholangitis the forgotten difficult disease/management of early and late cases.



TOPICS OF 2ND DAY

GERD UPDATES

SESSION 1

- Spectrum of gastro esophageal reflux disease.
- Laryngo pharyngeal reflux disease.
- How to differentiate between PPIs in the future?
- How to avoid complications of GERD.

SESSION 2

- What should we learn about NERD?
- Is there still a role for surgery in GERD management?
- Dual release PPI solved the problem of GERD with erosions.
- What about post injection and ligation therapy for bleeding esophageal varices is there a role for PPIs?

SESSION 3

- Side effects & complications of long term PPI therapy re-evaluated.
- Immediate release PPI what its impact in GERD manage met.
- Delayed release PPIs are still leading the market.

SESSION 4

- Helicobacter pylori and GERD management
- Toronto consensus for Helicobacter pylori treatment what is new?
- Should we treat all patients positive for Helicobacter pylori?



TOPICS OF 3RD DAY

POSTER PRESENTATIONS



CONGRESS PACKAGE

REGISTRATION

Egyptians > 500 L.E Expatriates > 300 \$

ACCOMMODATION PACKAGE 3 NIGHTS (FULL BOARD)

Sgl. Room >> Egyptians > 3500 L.E Expatriates > 750 \$

DbL. Room >> Egyptians > 4400 L.E Expatriates > 900 \$

Tpl. Room >> Egyptians > 5600 L.E Expatriates > 1200 \$



53 El-Makrizy Street, Roxy, Doctors Tower, Cairo, Egypt
Tel. : +20 (2) 24532 916/17 - Fax: +20 (2) 24 533 515
Mob. : +20 (10) 222 40 575 / +20 (10) 222 40 576
Email : alfa@alfamedical.org / info@alfamedical.org

WWW.ALFAMEDICAL.ORG